Filing Flows › Foghorn Therapeutics (FHTX) › Q3 2026
Foghorn Therapeutics (FHTX) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 9, 2026
Foghorn Therapeutics (FHTX) reported revenue of $83.5M for the third quarter 2026 (Q3 2026), +925% from a year earlier and +420% from the quarter before. Operating margin was 67.8%, net earnings $58.1M (69.6% of revenue).
Foghorn Therapeutics, Q3 2026: revenue $83.5M (+925% year over year), operating margin 67.8%, net earnings $58.1M, operating cash flow −$18.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $83.5M | +420% | +925% |
| Operating profit | $56.6M | — | — |
| Net earnings | $58.1M | — | — |
| Operating cash flow | −$18.2M | — | — |
What changed
Revenue was $83.5M in Q3 2026, up 925% year over year and up 420% from the previous quarter.
Operating profit was $56.6M, a 67.8% margin (up 294.7 points year over year). Total costs grew 1% against revenue growth of 925%. Net earnings were $58.1M. The effective tax rate was 0.0%.
Operating cash flow was −$18.2M. Non-cash charges added back $200K of depreciation and amortization and $2.5M of share-based compensation. Working capital and other items used $79.1M. Capital expenditures of $7K exceeded it, leaving free cash flow of −$18.2M.
Questions
What was Foghorn Therapeutics' revenue in the third quarter 2026?
Foghorn Therapeutics (FHTX) reported revenue of $83.5M for the third quarter 2026 (Q3 2026), +925% from a year earlier and +420% from the quarter before.
Was Foghorn Therapeutics profitable in the third quarter 2026?
Operating profit was $56.6M (67.8% of revenue) and net earnings $58.1M.